Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 9/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.43 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761125 | 0.98 | NUDT1 (0.52) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL4652224 | 0.83 | HRH4 (0.50) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL4653431 | 0.81 | SMN1; SMN2 (0.53) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL4653878 | 0.81 | SMN1; SMN2 (0.53) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL6399183 | 0.81 | NUDT1 (0.41) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| Hydrochloric Acid SCHEMBL4653618 | 0.80 | SMN1; SMN2 (0.51) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL5309809 | 0.79 | HRH4 (0.46) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| SCHEMBL7521998 | 0.78 | HRH4 (0.43) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| Minoxidil SCHEMBL638820 | 0.78 | SMN1; SMN2 (0.47) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 | |
| Minoxidil SCHEMBL29698 | 0.78 | SMN1; SMN2 (0.47) | NUDT1HRH4SMN1; SMN2CRHBPCRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050049232-A1 | Composition | LINDAU PAR (SE) | 2005-03-03 | — | — | US | disclosed |
| EP-1463483-A1 | NEW COMPOSITION | Ponsus Pharma AB (SE) | 2004-10-06 | — | — | EP | disclosed |
| WO-2003055454-A1 | NEW COMPOSITION | PONSUS PHARMA AB (SE) | 2003-07-10 | — | — | WO | disclosed |
| US-5772990-A | Composition for slowing down the loss of hair based on pyrimidine N-oxides triaminosubstituted or their sulfoconjugated | L'OREAL (FR) | 1998-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049232-A1 | Composition | CUTA, LIPG, LIPA | NUDT1 4169/4885HRH4 638/4885SMN1; SMN2 4641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.